185 related articles for article (PubMed ID: 27530235)
1. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.
Hathout Y; Conklin LS; Seol H; Gordish-Dressman H; Brown KJ; Morgenroth LP; Nagaraju K; Heier CR; Damsker JM; van den Anker JN; Henricson E; Clemens PR; Mah JK; McDonald C; Hoffman EP
Sci Rep; 2016 Aug; 6():31727. PubMed ID: 27530235
[TBL] [Abstract][Full Text] [Related]
2. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
[TBL] [Abstract][Full Text] [Related]
3. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
[TBL] [Abstract][Full Text] [Related]
4. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy.
Hathout Y; Liang C; Ogundele M; Xu G; Tawalbeh SM; Dang UJ; Hoffman EP; Gordish-Dressman H; Conklin LS; van den Anker JN; Clemens PR; Mah JK; Henricson E; McDonald C
Sci Rep; 2019 Aug; 9(1):12167. PubMed ID: 31434957
[TBL] [Abstract][Full Text] [Related]
5. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
[TBL] [Abstract][Full Text] [Related]
7. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
[TBL] [Abstract][Full Text] [Related]
8. Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.
Conklin LS; Merkel PA; Pachman LM; Parikh H; Tawalbeh S; Damsker JM; Cuthbertson DD; Morgan GA; Monach PA; Hathout Y; Nagaraju K; van den Anker J; McAlear CA; Hoffman EP
Steroids; 2018 Dec; 140():159-166. PubMed ID: 30352204
[TBL] [Abstract][Full Text] [Related]
9. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
Kourakis S; Timpani CA; Campelj DG; Hafner P; Gueven N; Fischer D; Rybalka E
Orphanet J Rare Dis; 2021 Mar; 16(1):117. PubMed ID: 33663533
[TBL] [Abstract][Full Text] [Related]
10. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
12. Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study.
Smy L; Shaw K; Amstutz U; Staub M; Chaudhry S; Smith A; Carleton B; Koren G
Clin Biochem; 2018 Jun; 56():26-32. PubMed ID: 29673814
[TBL] [Abstract][Full Text] [Related]
13. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
[TBL] [Abstract][Full Text] [Related]
16. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy].
Sun SC; Peng YS; He JB
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D in corticosteroid-naïve and corticosteroid-treated Duchenne muscular dystrophy: what dose achieves optimal 25(OH) vitamin D levels?
Alshaikh N; Brunklaus A; Davis T; Robb SA; Quinlivan R; Munot P; Sarkozy A; Muntoni F; Manzur AY;
Arch Dis Child; 2016 Oct; 101(10):957-61. PubMed ID: 27246070
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
[TBL] [Abstract][Full Text] [Related]
19. A 19-year-old ambulant Duchenne patient with stunted growth on long-term corticosteroids.
Merlini L
Neuromuscul Disord; 2014 May; 24(5):417-8. PubMed ID: 24631208
[No Abstract] [Full Text] [Related]
20. [Systemic corticosteroid therapy in rheumatology, advantages and risks].
Gerster JC; So AK; Burckhardt P
Praxis (Bern 1994); 1998 Aug; 87(33):1024-7. PubMed ID: 9747132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
